"Success in moderate-to-severe TBI opens up other possibilities for NNZ-2566 as an IV drug. Obviously if NNZ-2566 is successful in non-penetrating TBI, Neuren will look to explore its use in penetrating TBI, in stroke, in cardiac arrest and neonatal asphyxia, and in non-convulsive seizures associated with other CNS conditions. Together this has potential to make NNZ-2566 a blockbuster drug.
An oral NNZ-2566 formulation is coming for mild TBI.
In mid-2010 Neuren initiated development of an oral NNZ-2566 formulation for use in mild TBI as well as stroke recovery. This drug would further extend the NNZ-2566 franchise, opening up its use in transient ischemic attacks (ie ‘mini strokes’), in chemotherapy-induced neuropathy and in a rare autism spectrum disorder called Rett Syndrome as well as other autism spectrum disorders. Neuren believes that it can complete development of oral NNZ-2566 late in 2011 and take this into the clinic for a mild TBI trial in mid-2012."
NEU Price at posting:
2.3¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)